Smith–Lemli–Opitz Syndrome
Publisher
Springer New York
Reference54 articles.
1. Abuelo, D. N., Tint, G. S., Kelley, R., et al. (1995). Prenatal detection of the cholesterol biosynthetic defect in the Smith–Lemli–Opitz syndrome by the analysis of amniotic fluid sterols. American Journal of Medical Genetics, 56, 281–285. 2. Boland, M. R., & Tatonetti, N. P. (2016). Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: A systematic review. Pharmacogenomics Journal. 12 July 2016. [Epub ahead of print]. 3. Bradley, L. A., Palomaki, G. E., Knight, G. J., et al. (1999). Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith–Lemli–Opitz (RSH) syndrome fetuses. American Journal of Medical Genetics, 82, 355–358. 4. Cunniff, C., Kratz, L. E., Moser, A., et al. (1997). Clinical and biochemical spectrum of patients with RSH/Smith–Lemli–Opitz syndrome and abnormal cholesterol metabolism. American Journal of Medical Genetics, 68, 263–269. 5. Curry, C. J., Carey, J. C., Holland, J. S., et al. (1987). Smith–Lemli–Opitz syndrome II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. American Journal of Medical Genetics, 26, 45–57.
|
|